Introduction

Acute kidney injury (AKI) is well recognized for its impact on the outcome of patients admitted to intensive care units (ICUs). When AKI requiring renal replacement therapy (RRT) occurs, hospital mortality is high, exceeding 50% [1–4]. Mortality rates have changed little over the past few decades despite the significant advances in dialytic and intensive care technology [5]. This could be due to the increasing age of the patients, higher comorbidities, and/or greater illness severity. Outcome prediction in this selected high-risk collective is challenging due to the lack of appropriate biomarkers. Thus, the identification of outcome-specific biomarkers in this patient population is a major goal in critical care nephrology.

Recent studies in the field of early detection of AKI have proposed many biomarkers for the early detection of AKI. A systematic review of publications, which evaluated the accuracy and reliability of serum and urinary biomarkers in human subjects when used to diagnose the established AKI or early AKI, or to risk stratify patients with AKI, indicated that serum cystatin C (CysC), urine interleukin-18 (IL-18), and urine kidney injury molecule-1 (KIM-1) performed best for the differential diagnosis of established AKI. Serum CysC and urine neutrophil gelatinase-associated lipocalin (NGAL), IL-18, glutathione-S-transferase-π, and γ-glutathione-S-transferase performed best for the early diagnosis of AKI. Urine N-acetyl-β-D-glucosaminidase, KIM-1, and IL-18 performed best for mortality risk prediction after AKI [7].

Although these biomarkers have a defined role in the early detection of AKI, little is known about the diagnostic and prognostic utility of these biomarkers in patients with established AKI requiring RRT. Therefore, we aimed to prospectively evaluate the correlation between different biomarkers (serum CysC, NGAL, and IL-18) and scoring systems [Sequential Organ

Abstract

**Background:** Acute kidney injury (AKI) requiring renal replacement therapy (RRT) in critically ill patients results in a high hospital mortality. Outcome prediction in this selected high-risk collective is challenging due to the lack of appropriate biomarkers. The aim of this study was to identify outcome-specific biomarkers in this patient population.

**Methodology/Principal Findings:** Serum samples were collected from 101 critically ill patients with AKI at the initiation of RRT in intensive care units (ICUs) of a tertiary care university hospital between August 2008 and March 2011. Measurements of serum levels of cystatin C (CysC), neutrophil gelatinase-associated lipocalin, and interleukin-18 (IL-18) were performed. The primary outcome measure was hospital mortality. The observed overall mortality rate was 56.4% (57/101). Multiple logistic regression analysis indicated that the serum IL-18 and CysC concentrations and Acute Physiology and Chronic Health Evaluation III (APACHE III) scores determined on the first day of RRT were independent predictors of hospital mortality. The APACHE III score had the best discriminatory power (0.872 ± 0.041, p < 0.001), whereas serum IL-18 had the best Youden index (0.65) and the highest correctness of prediction (83%). Cumulative survival rates at 6-month follow-up following hospital discharge differed significantly (p < 0.001) for serum IL-18 < 1786 pg/ml vs. ≥1786 pg/ml in these critically ill patients.

**Conclusions:** In this study, we confirmed the grave prognosis for critically ill patients at the commencement of RRT and found a strong correlation between serum IL-18 and the hospital mortality of ICU patients with dialysis-dependent AKI. In addition, we demonstrated that the APACHE III score has the best discriminative power for predicting hospital mortality in these critically ill patients.
Definitions

Sampling and quantification of serum CysC, NGAL and IL-18

Patient information and data collection

This is a prospective study, conducted between August 2008 and March 2011 in ICUs at a tertiary care referral center in Taiwan. The critically ill patients with AKI requiring RRT were enrolled. Exclusion criteria were as follows: patients or their next of kin who were unable or declined to provide written informed consent; pediatric patients (ages ≤18 years); patients with any dialysis treatment before admission to the ICU; patients with end-stage renal failure; duration of ICU stay after first RRT <24 h; and patients who had undergone renal transplantation. Readmitted patients were also excluded from this study.

The RRT modality was chosen by combining the clinical judgment of the consulting nephrologist with the input of the attending critical care physician. Patients who were perceived to be hemodynamically stable were treated with IHD. Hemodynamically unstable patients were typically prescribed CRRT. Serum samples for quantification of CysC, NGAL, and IL-18 were available from all patients at the start of the RRT. Prospectively collected data were as follows: demographics; reason for ICU admission and RRT; primary diagnosis; routine chemistry tests; SOFA and APACHE II and III scores on the first day of RRT in the ICU; duration of hospitalization; and outcome. The primary study outcome was hospital mortality. Follow-up after 6 months after hospital discharge was performed via chart record or a telephone interview.

Sampling and quantification of serum CysC, NGAL and IL-18

Blood samples were collected in nonheparinized tubes immediately before initiation of RRT and were centrifuged at 1500 rpm for 5 minutes. Serum samples were subsequently stored at −80°C until assayed. Serum CysC and NGAL were measured in duplicate by single ELISA (R&D Systems, Minneapolis, MN, USA). Serum IL-18 was measured in duplicate by single ELISA (Medical and Biologic Laboratories, Nagoya, Japan), according to the manufacturer’s instructions.

Definitions

Severe sepsis was defined according to modified American College of Chest Physicians and Society of Critical Care Medicine consensus criteria [8]. Patients with proven or suspected infection, two or more systemic inflammatory response syndrome criteria and an infection-induced organ dysfunction were classified as having severe sepsis. Septic shock was diagnosed when the systolic arterial blood pressure remained less than 90 mmHg despite adequate fluid resuscitation. Patients with AKI on the first day of RRT were classified as Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal failure (RIFLE) according to risk, injury, and failure categories, respectively [9]. Illness severity was assessed by using the APACHE II and III scores [10,11] and the SOFA score [12].

The worst physiological and biochemical values on the day of initial RRT in the ICU were recorded. These systems have been validated to predict the outcomes of critically ill patients [13,14]. The treatment of RRT in critically ill patients was indicated on the basis of clinical grounds, including refractory hyperkalemia, resistant fluid overload, severe persistent metabolic acidosis, and overt uremic symptoms, including uremic pericarditis and encephalopathy [15].

Statistical analysis

Descriptive statistics are expressed as means ± standard error (SE). Primary analysis compared hospital survivors with nonsurvivors. All variables were tested for normal distribution using the Kolmogorov-Smirnov test. Student’s t-test was applied to compare the means of continuous variables and normal distribution data. Otherwise, the Mann-Whitney U-test was employed. Categorical data were tested using the Chi-square test. We assessed the risk factors for hospital mortality by using univariate analysis, and the variables that were found to be statistically significant (p<0.05) in the univariate analysis were included in the multivariate analysis. Multiple logistic regression model based on the forward elimination of data was used to analyze these variables.

Hospital mortality and short-term prognosis

Between August 2008 and March 2011, 101 patients with AKI requiring RRT in ICUs were enrolled in this study. The 101 consecutive critically ill patients with AKI were treated with continuous renal replacement therapy (CRRT) (n = 27) or intermittent hemodialysis (IHD) (n = 74). No patients met the RIFLE criteria for loss or end-stage renal disease categories. Patient median age was 60 years; 68 were male (67%) and 33 were female (33%). Overall, hospital mortality for the entire group was 56.4% (57/101). Of the 57 non-survivors, 52 patients (91.2%) had sepsis and 19 patients (33.3%) had liver cirrhosis (Table 1). Table 2 describes the reasons for ICU admission and indications for RRT. The most frequent indications for RRT were anuria/oliguria.

Results

Subject characteristics

Between August 2008 and March 2011, 101 patients with AKI requiring RRT in ICUs were enrolled in this study. The 101 consecutive critically ill patients with AKI were treated with continuous renal replacement therapy (CRRT) (n = 27) or intermittent hemodialysis (IHD) (n = 74). No patients met the RIFLE criteria for loss or end-stage renal disease categories. Patient median age was 60 years; 68 were male (67%) and 33 were female (33%). Overall, hospital mortality for the entire group was 56.4% (57/101). Of the 57 non-survivors, 52 patients (91.2%) had sepsis and 19 patients (33.3%) had liver cirrhosis (Table 1). Table 2 describes the reasons for ICU admission and indications for RRT. The most frequent indications for RRT were anuria/oliguria.

Hospital mortality and short-term prognosis

Table 3 lists goodness-of-fit, as measured by the Hosmer-Lemeshow chi-square statistic of predicted hospital mortality risk, the predictive accuracy of serum CysC, IL-18, and NGAL as well as APACHE II and III and SOFA scores. We also compared the
Serum IL-18 Predicted Outcome of AKI on RRT

Table 1. Comparison of hospital survivors and non-survivals after commencement of renal replacement therapy.

|                          | All Patients (n = 101) | Survivors (n = 44) | Non-survivors (n = 57) | p-value |
|--------------------------|------------------------|--------------------|------------------------|---------|
| Age (years)              | 60±2                   | 60±3               | 58±2                   | NS (0.736) |
| Length of hospital stay (day) | 47±4                  | 57±6               | 39±5                   | 0.031   |
| Male, n (%)              | 68 (67)                | 29 (66)            | 39 (68)                | NS (0.790) |
| RRT modality (IHD), n (%) | 74 (73)                | 36 (82)            | 38 (67)                | NS (0.088) |
| Diabetes mellitus, n (%) | 30 (30)                | 16 (36)            | 14 (25)                | NS (0.198) |
| Hypertension, n (%)      | 29 (29)                | 16 (36)            | 13 (23)                | NS (0.135) |
| CKD, n (%)               | 43 (43)                | 22 (50)            | 21 (37)                | NS (0.185) |
| Sepsis, n (%)            | 73 (72)                | 21 (48)            | 52 (91)                | <0.001  |
| Liver cirrhosis, n (%)   | 20 (20)                | 1 (2)              | 19 (33)                | <0.001  |
| Body weight (kg)         | 63±1                   | 63±2               | 64±2                   | NS (0.893) |
| Serum Cys C (mg/L)       | 4.9±0.2                | 4.0±0.3            | 5.7±0.3                | <0.001  |
| Serum IL-18 (pg/mL)      | 2179±149               | 1265±79            | 2873±211               | <0.001  |
| Serum NGAL (ng/mL)       | 795±66                 | 513±42             | 1012±104               | <0.001  |
| PaO2/FiO2                | 218±10                 | 228±16             | 212±14                 | NS (0.464) |
| GCS (points)             | 12.6±0.4               | 13.3±0.5           | 12.2±0.5               | NS (0.122) |
| MAP (mmHg)               | 84±2                   | 88±3               | 82±3                   | NS (0.168) |
| Serum Creatinine (mg/dL) | 4.8±0.2                | 4.7±0.3            | 4.9±0.3                | NS (0.207) |
| Urine output (mL/day)    | 343±44                 | 369±41             | 327±68                 | NS (0.652) |
| Sodium (mEq/L)           | 139±1                  | 139±1              | 139±1                  | NS (0.980) |
| Leukocytes (x10³/µL)     | 16.6±1.1               | 15.5±1.2           | 17.3±1.6               | NS (0.438) |
| Hemoglobin (g/dL)        | 9.6±0.2                | 9.8±0.4            | 9.4±0.2                | NS (0.494) |
| CRP (mg/L)               | 123±10                 | 123±16             | 124±20                 | NS (0.972) |
| RIFLE (Risk/Injury/Failure) | 5/15/81               | 3/9/32             | 2/6/49                 | NS (0.124) |
| SOFA (mean ± SE)         | 11.1±0.4               | 9.2±0.4            | 12.4±0.5               | <0.001  |
| APACHE II (mean ± SE)    | 18.8±0.7               | 16.8±1.1           | 20.1±0.9               | 0.026   |
| APACHE III (mean ± SE)   | 93.2±2.2               | 77.2±1.4           | 103.3±2.7              | <0.001  |

APACHE, Acute Physiology and Chronic Health Evaluation; CKD, chronic kidney disease; CRP, C reactive protein; CysC, cystatin C; FiO2, fraction of inspired oxygen; GCS, Glasgow coma scale; IHD, intermittent hemodialysis; IL-18, interleukin-18; MAP, mean arterial pressure; NGAL: neutrophil gelatinase-associated lipocalin; NS, not significant; PaO2, partial pressure of oxygen; RIFLE, Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal failure; RRT, renal replacement therapy; SE, standard error; SOFA, sequential organ failure assessment.

doi:10.1371/journal.pone.0066028.t001

discriminatory value of these AKI biomarkers and the three scoring systems. The AUROC analysis verified that the APACHE III score had the best discriminatory power.

To assess the predictive value of selected cut-offs for predicting hospital mortality, the sensitivity, specificity, and overall correctness of prediction were determined. Table 4 summarizes the data calculated using the cutoff point providing the best Youden index. Serum IL-18 had the best Youden index and the highest overall correctness of prediction. The overall 1-month, 3-month and 6-month mortality rates were 48.5% (49/101), 57.4% (58/101) and 57.4% (58/101) respectively. 1-month, 3-month and 6-month mortality rates significantly differed below and above the cutoff point of serum IL-18 = 1786 pg/mL (21.8% vs. 80.4%, p<0.001; 27.3% vs. 93.5%, p<0.001 and 27.3% vs. 93.5%, p<0.001 respectively). Figure 1 illustrates that 6-month cumulative survival rates differed significantly (p<0.001) between the two groups divided by the cutoff point of serum IL-18 = 1786 pg/mL in the study population.

Univariate analysis identified 8 (Table 5) out of 25 variables (Table 1, except the length of hospital stay) as prognostically valuable. Multivariate analysis identified the following variables as having independent prognostic significance: serum IL-18 and CysC levels and APACHE III score (Table 5). Regression coefficients of these variables were utilized to calculate a logit of death for each patient as follows:

The logarithm of death odds = −18.052+0.802× serum CysC +0.001× serum IL-18 +0.142× APACHE III.

Discussion

Several studies have identified a mortality rate of more than 50% in critically ill patients with AKI requiring RRT [1–4]. The hospital mortality rate for patients in the present study was 56.4%. The analytical results verify that prognosis is grave for this patient subgroup. This study also confirmed that APACHE III score and serum IL-18 and CysC levels on RRT day 1 were strongly correlated with hospital mortality.

A large study of healthy, middle-aged European men showed that serum IL-18 concentration is an independent predictor of coronary events [17]. In addition, variation within the IL-18 gene is known to influence the circulating concentrations of IL-18 and clinical outcome in patients with coronary heart disease [18]. IL-18 is an important regulator of both innate and acquired immune responses [19]. It is present in human atherosclerotic lesions, and at higher concentrations in unstable plaques [20]. In animal models, IL-18 is shown to influence the circulating concentrations of IL-18 and CysC levels and APACHE III score (Table 5). Regression coefficients of these variables were utilized to calculate a logit of death for each patient as follows:

The logarithm of death odds = −18.052+0.802× serum CysC +0.001× serum IL-18 +0.142× APACHE III.

Discussion

Several studies have identified a mortality rate of more than 50% in critically ill patients with AKI requiring RRT [1–4]. The hospital mortality rate for patients in the present study was 56.4%. The analytical results verify that prognosis is grave for this patient subgroup. This study also confirmed that APACHE III score and serum IL-18 and CysC levels on RRT day 1 were strongly correlated with hospital mortality.

A large study of healthy, middle-aged European men showed that serum IL-18 concentration is an independent predictor of coronary events [17]. In addition, variation within the IL-18 gene is known to influence the circulating concentrations of IL-18 and clinical outcome in patients with coronary heart disease [18]. IL-18 is an important regulator of both innate and acquired immune responses [19]. It is present in human atherosclerotic lesions, and at higher concentrations in unstable plaques [20]. In animal models, IL-18 is shown to influence the circulating concentrations of IL-18 and CysC levels and APACHE III score (Table 5). Regression coefficients of these variables were utilized to calculate a logit of death for each patient as follows:

The logarithm of death odds = −18.052+0.802× serum CysC +0.001× serum IL-18 +0.142× APACHE III.
models, IL-18 administration leads to increases in atherosclerotic lesion size and promotes increased numbers of T-lymphocytes in the lesion [21], suggesting that it may be of pathogenic importance in tissues. The authors of this study group previously demonstrated that APACHE II score, serum sodium concentrations, urinary NGAL, and serum IL-18 on day 1 of coronary care unit admission are independent predictors of 180-day mortality [22]. In the present study, serum IL-18 level showed significantly better discriminatory power than the APACHE II score at the initiation of RRT for hospital mortality prediction (Table 3). Serum IL-18 also had the best Youden index and the highest overall correctness of prediction (Table 4). Furthermore, patients with serum concentrations of IL-18 >1786 pg/mL on RRT day 1 were associated with an extremely high half-year mortality rate of 93% (40/43) (Figure 1).

Cystatin C is a 13-kDa protein that is normally freely filtered, completely reabsorbed, and catabolized within the proximal tubule [23]. It is a marker of glomerular filtration and has performed extremely well in identifying established AKI. In patients with AKI, serum cystatin C level performs similarly to

Table 2. Primary diagnosis for intensive care unit admission and renal replacement therapy indication between hospital survivors and non-survivors.

| Primary ICU admission                  | All Patients (n = 101) | Survivors (n = 44) | Non-survivors (n = 57) | p    |
|--------------------------------------|-----------------------|--------------------|------------------------|------|
| Respiratory failure with ventilator  | 39 (39)               | 20 (45)            | 19 (33)                | NS (0.215) |
| Septic shock                         | 8 (8)                 | 0 (0)              | 8 (14)                 | 0.010|
| Severe UGI bleeding                  | 11 (11)               | 5 (11)             | 6 (11)                 | NS (0.894) |
| Acute decompensated liver failure    | 14 (14)               | 1 (2)              | 13 (23)                | 0.003|
| Postoperative care                   | 18 (18)               | 12 (27)            | 6 (11)                 | 0.029|
| Others a                             | 11 (11)               | 6 (14)             | 5 (9)                  | NS (0.437) |

| Primary reason for RRT               |                       |                    |                        |      |
|--------------------------------------|-----------------------|--------------------|------------------------|------|
| Anuria/Oliguria (>12 hours)          | 61 (60)               | 24 (55)            | 37 (65)                | NS (0.291) |
| AKI in progression                   | 22 (22)               | 10 (23)            | 12 (21)                | NS (0.840) |
| Oliguria/AKI with metabolic acidosis | 7 (7)                 | 1 (2)              | 6 (11)                 | NS (0.105) |
| Oliguria/AKI with hyperkalemia       | 5 (5)                 | 4 (9)              | 1 (2)                  | NS (0.164) |
| Oliguria/AKI with pulmonary edema    | 6 (6)                 | 5 (11)             | 1 (2)                  | NS (0.083) |

| AKI: acute kidney injury; ICU: intensive care unit; RRT, renal replacement therapy; UGI, upper gastrointestinal.
| a, Multifactor related. |

Table 3. Comparison of calibration and discrimination of the biomarkers and scoring systems on the first day of renal replacement therapy in predicting hospital mortality.

| Calibration | Discrimination |
|-------------|----------------|
| Serum CysC  | 15.458 8 0.051 0.771 ± 0.055 0.662–0.880 < 0.001 |
| Serum IL-18 | 7.865 8 0.447 0.849 ± 0.039 0.772–0.926 < 0.001 |
| Serum NGAL | 7.872 8 0.446 0.765 ± 0.055 0.658–0.931 < 0.001 |
| SOFA        | 11.750 8 0.163 0.767 ± 0.054 0.661–0.872 < 0.001 |
| APACHE II   | 8.803 8 0.359 0.644 ± 0.063 0.521–0.767 0.024 |
| APACHE III  | 12.389 8 0.134 0.872 ± 0.041 0.792–0.951 < 0.001 |

APACHE, Acute Physiology and Chronic Health Evaluation; AUROC, areas under the receiver operating characteristic curve; CI, confidence intervals; CysC, cystatin C; df, degree of freedom; IL-18, interleukin-18; NGAL, neutrophil gelatinase-associated lipocalin; RRT, renal replacement therapy; SE, standard error; SOFA, sequential organ failure assessment.

Figure 1. Cumulative survival for 101 critically ill patients with acute kidney injury requiring renal replacement therapy (RRT) according to a below and above cut-off of serum interleukin-18 (IL-18) level 1786 pg/mL measured before the initiation of RRT.

doi:10.1371/journal.pone.0066028.g001
serum creatinine level, serum urea nitrogen level, and urine output in predicting dialysis requirement or in-hospital death [24]. Urinary cystatin C was independently associated with death within 30 days in critically ill patients [25]. However, the predictive utility of CysC in critically ill patients with established AKI requiring RRT is poorly characterized. Apart from the serum concentration of IL-18, this study has demonstrated that APACHE III score and serum CysC level are independently associated with hospital mortality.

Because AKI occurs in patients with varying profiles and diverse disease etiologies, predicting the outcome of patients with AKI requiring RRT is difficult. The APACHE system assumes that the core mission of intensive care is treating disease and maintaining physiological homeostasis. Physiological abnormalities are common among ICU patients, and the extent of derangement is an objective and reproducible measure of illness severity [26]. In this study, the APACHE III score, but not the APACHE II score, showed good calibration and the best discriminatory power, thus indicating the superior prognostic accuracy of APACHE III when compared with the other scoring systems evaluated in this patient population. Moreover, the pathogenesis of experimental AKI secondary to endotoxemia is the compensation for impaired hemodynamics by up-regulation of vasoconstrictor systems and renal vasoconstriction [13,27]. Although septic AKI is an independent predictor of mortality, the leading causes of death associated with AKI are non-renal complications, typically those related to multi-organ dysfunction.

Despite the promising results obtained in this study, several important limitations should be recognized. First, this study was conducted in a single institution. Consequently, the results may not be directly extrapolated to other patient populations. Second, predictions vary among individuals. Accordingly, a prediction is only an approximate indicator of mortality risk in specific subjects. Third, we examined scoring systems only during the first day of RRT support, although these models were developed and calculated on the first day of ICU admission. Fourth, liver cirrhosis was largely attributed to hepatitis B viral infection (55%) in this investigation. The number of patients with cirrhosis (n = 20) and outcome events were insufficient to determine independent risk factors for hospital mortality by using multivariate techniques.

### Table 4. Subsequent hospital mortality predicted on the commencement of renal replacement therapy.

| Predictive Factors | Cutoff Point | Youden Index | Sensitivity (%) | Specificity (%) | Overall Correctness (%) |
|--------------------|--------------|--------------|----------------|-----------------|-------------------------|
| Serum CysC (mg/L)  | 4.3a         | 0.49         | 79             | 70              | 75                      |
| Serum IL-18 (pg/mL)| 1786a        | 0.65         | 77             | 88              | 83                      |
| Serum NGAL (ng/mL)| 873a         | 0.42         | 51             | 91              | 71                      |
| SOFA               | 13a          | 0.46         | 57             | 89              | 73                      |
| APACHE II          | 15a          | 0.22         | 67             | 55              | 61                      |
| APACHE III         | 96a          | 0.60         | 71             | 89              | 80                      |

APACHE, Acute Physiology and Chronic Health Evaluation; CysC, cystatin C; IL-18, interleukin-18; NGAL: neutrophil gelatinase-associated lipocalin; RRT, renal replacement therapy; SOFA, sequential organ failure assessment.

*Value giving the best Youden index.

**Table 5. Logistic regression analysis for hospital mortality, according to baseline prognostic factors on the first day of renal replacement therapy.**

| Parameter           | Beta coefficient | Standard error | Odds ratio (95%CI) | p  |
|---------------------|------------------|----------------|--------------------|----|
| Univariate logistic regression |                   |                |                    |    |
| Sepsis              | 2.501            | 0.559          | 12.190 (4.076–36.452) | <0.001 |
| Liver cirrhosis     | 3.019            | 1.050          | 20.462 (2.614–160.151) | 0.004 |
| Serum CysC          | 0.480            | 0.134          | 1.615 (1.242–2.101)   | <0.001 |
| Serum IL-18         | 0.002            | 0.000          | 1.002 (1.001–1.003)   | <0.001 |
| Serum NGAL          | 0.002            | 0.001          | 1.002 (1.001–1.004)   | 0.001 |
| SOFA                | 0.253            | 0.075          | 1.288 (1.112–1.492)   | 0.001 |
| APACHE II           | 0.081            | 0.036          | 1.084 (1.011–1.163)   | 0.024 |
| APACHE III          | 0.116            | 0.025          | 1.123 (1.069–1.180)   | <0.001 |
| Multivariate logistic regression |                   |                |                    |    |
| Serum CysC          | 0.802            | 0.282          | 2.229 (1.283–3.872)   | 0.004 |
| Serum IL-18         | 0.001            | 0.001          | 1.001 (1.000–1.002)   | 0.008 |
| APACHE III          | 0.142            | 0.057          | 1.152 (1.031–1.288)   | 0.012 |
| Constant            | −18.052          | 5.662          | -                  | -   |

APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence intervals; CysC, cystatin C; IL-18, interleukin-18; NGAL: neutrophil gelatinase-associated lipocalin; RRT, renal replacement therapy; SOFA, sequential organ failure assessment.

doi:10.1371/journal.pone.0066028.t004
doi:10.1371/journal.pone.0066028.t005
Finally, sequential measurement of these AKI biomarkers or other AKI biomarkers (e.g., kidney injury molecule-1, liver fatty acid-binding proteins) and scoring systems (e.g., daily, weekly) may reflect the dynamic aspects of clinical diseases and thus provide superior information on mortality risk. This study has confirmed the grave prognosis for critically ill patients with AKI requiring RRT. It has also elucidated that the predictors of APACHE III score, and serum CysC and IL-18 concentrations on the first day of RRT are independently associated with hospital mortality. Because of the relatively small sample size used in this study, the predictive roles of APACHE III score and serum CysC and IL-18 levels require further external validation.

Author Contributions
Conceived and designed the experiments: YCC CCH JTF CWY. Performed the experiments: YCC CYL CHC PCF. Analyzed the data: YCC CYL CHC PCF YCT MYC CCJ. Contributed reagents/materials/analysis tools: PCF YCT MYC CCJ CCH JTF CWY. Wrote the paper: YCC CYL CHC.

References
1. Ostermann M, Chang RW (2009) Correlation between parameters at initiation of renal replacement therapy and outcome in patients with acute kidney injury. Crit Care 13: R175.
2. Lin YF, Ko VJ, Chu TS, Chen YS, Wu VC, et al. (2009) The 90-day mortality and the subsequent renal recovery in critically ill surgical patients requiring acute renal replacement therapy. Am J Surg 198: 325–332.
3. Rocha E, Soares M, Valentie C, Nogueira L, Bonomo H Jr., et al. (2009) Outcomes of critically ill patients with acute kidney injury and end-stage renal disease requiring renal replacement therapy: a case-control study. Nephrol Dial Transplant 24: 1925–1930.
4. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, et al. (2005) Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294: 813–818.
5. Ricci Z, Ronco C (2009) Today’s approach to the critically ill patient with acute kidney injury. Blood Purif 27: 127–134.
6. Ku¨mpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K, et al. (2010) Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care 14: R9.
7. Coca SG, Yalvaruyt R, Concato J, Parikh CR (2008) Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int 73: 1008–1016.
8. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864–874.
9. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, et al. (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8: R204–R212.
10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: A severity of disease classification system. Crit Care Med 13: 818–829.
11. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, et al. (1991) The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100: 1619–1636.
12. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonc¸a A, et al. (1996) The APACHE II severity of disease classification system. Crit Care Med 23: 852–860.
13. Chen YC, Jenq CC, Tian YC, Chang MY, Lin CY, et al. (2009) Rifle classification for predicting in-hospital mortality in critically ill sepsis patients. Shock 31: 139–145.
14. Lin CY, Kao KC, Tian YC, Jenq CC, Chang MY, et al. (2009) The RIFLE score increases the accuracy of outcome prediction in patients with acute respiratory distress syndrome undergoing open lung biopsy. Respiration 77: 390–406.
15. Davenport A, Bouman C, Kirpalani A, Skippen P, Tolwani A, et al. (2008) Delivery of renal replacement therapy in acute kidney injury: What are the key issues? Clin J Am Soc Nephrol 3: 869–875.
16. Youden WJ (1950) Index for rating diagnosis tests. Cancer 3: 32–35.
17. Blankenberg S, Luc G, Ducimetie`re P, Arveiler D, Ferrieres J, et al. (2003) Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 108: 2435–2439.
18. Tiret L, Godelroy T, Labos E, Nicaud V, Tregouet DA, et al. (2005) Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 112: 643–650.
19. Gracie JA, Robertson SE, McInnes IB (2003) Interleukin-18. J Leukoc Biol 73: 213–224.
20. Malat Z, Corbaz A, Scocace A (2003) Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104: 1598–1603.
21. Whitman SC, Ravisankar P, Daugherty A (2002) Interleukin-18 enhances atherosclerosis in apolipoprotein E(–/–) mice through release of interferon-gamma. Circ Res 90: E34–E38.
22. Chen TH, Chang CH, Lin CY, Jenq CC, Chang MY, et al. (2012) Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. PLoS One 7: e32328.
23. Westhuyzen J (2006) Cystatin C: a promising marker and predictor of impaired renal function. Ann Clin Lab Sci 36: 387–394.
24. Perianayagam MC, Seabra VF, Tighiouart H, Liangos O, Jaber BL (2009) Serum cystatin C for prediction of dialysis requirement or death in acute kidney injury: a comparative study. Am J Kidney Dis 54: 1025–1033.
25. Nejat M, Pickering JW, Walker RJ, Westhuyzen J, Shaw GM, et al. (2010) Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care 14: R65.
26. Zimmerman JK, Kzamer AA (2006) Outcome prediction in critical care: the Acute Physiology and Chronic Health Evaluation models. Curr Opin Crit Care 14: 491–497.
27. Fan PG, Chang CH, Tsai MH, Lin SM, Jenq CC, et al. (2012) Predictive value of acute kidney injury in medical intensive care patients with sepsis originating from different infection sites. Am J Med Sci 343: 83–89.